Physical Fitness in Celiac Disease Patients - the Effect of a Gluten Free Diet

Overview

Evaluating the effect of Celiac disease (CD) and gluten free diet (GFD) on physical fitness parameters among CD subjects. The CD subjects will be compared to healthy controls.

This is a prospective observational cohort study. The study would take place at Meir Medical Center (Kfar-Saba, Israel), a secondary-level academic hospital. The investigators will enroll 50 newly diagnosed CD subjects. The diagnosis will be in accordance with the European Society for Gastroenterology Hepatology and Nutrition guidelines for the diagnosis of CD from 2012 (6). The investigators will also enroll 50 control subjects. The control subjects are children visiting the pediatric gastroenterology clinic. Before enrollment the investigators will rule out chronic conditions involving the gastrointestinal tract including CD. All subjects will be enrolled after providing an informed consent and signing the consent form. The investigators will obtain the following measurements and evaluations at and 6 months after enrollment: 1. Anthropometric measurements: Height, weight, body mass index (BMI) and total body fat will be evaluated using a TANITA scale. The z-score for each parameter will be recorded. 2. A Godin leisure-time exercise questionnaire (7) will be filled by the subjects and their parents 3. Evaluation of physical fitness by the Eurofit fitness testing (8). This series of physical fitness tests was developed to evaluate speed, stamina and strength in school-aged children. 1. Flamingo balance test 2. Seat and reach test 3. Standing broad jump test 4. Handgrip test 5. Sit-ups test 6. Bent arm hang test 7. Twenty meter endurance shuttle run test 8. Wingate anaerobic fitness test 4. Bone speed of sound test will be performed by a bone sonometer - a non-invasive ultrasound based measurement of bone density. 5. CD subjects will be evaluated for adherence to GFD via questioning by a pediatric gastroenterologist and a clinical dietitian and by serum tissue transglutaminase immunoglobulin A (IgA) level (or serum deamidated gliadin peptide immunoglobulin G level in IgA deficient subjects). This is part of the normal follow-up of CD patients.

Conditions

Eligibility

Locations (1)

Outcomes